On August 27, 2020 Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, reported that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 1,666,667 shares of common stock of the Company, at a price to the public of $2.10 per share, less underwriting discounts and commissions (Press release, Oncternal Therapeutics, AUG 27, 2020, View Source [SID1234564116]). The closing of the offering is expected to occur on or about September 1, 2020, subject to satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.

The Company also has granted to the underwriter a 30-day option to purchase up to an additional 250,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Oncternal, before deducting underwriting discounts and commissions and offering expenses and assuming no exercise of the underwriter’s option to purchase additional common stock, are expected to be approximately $3.5 million. The Company intends to use the net proceeds from this offering for general corporate purposes, including expenses related to the clinical and preclinical development of cirmtuzumab and TK216, preclinical development of its ROR1 CAR-T program, and for working capital.

The shares of common stock are being offered by Oncternal pursuant to a "shelf" registration statement on Form S-3 (File No. 333-222268) previously filed with the Securities and Exchange Commission (the "SEC") on December 22, 2017 and declared effective by the SEC on January 5, 2018. The offering of the shares of common stock is made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the shares of common stock being offered will be filed with the SEC. Electronic copies of the preliminary prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at View Source or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (646) 975-6996 or e-mail at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On August 27, 2020 Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, reported that management will present at the following upcoming virtual investor conferences (Press release, Arcus Biosciences, AUG 27, 2020, View Source [SID1234564115]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi 15th Annual BioPharma Virtual Conference, Wednesday, September 9 at 1:30 pm ET
2020 Cantor Global Virtual Healthcare Conference, Wednesday, September 16 at 4:40pm ET
Morgan Stanley Virtual 18th Annual Global Healthcare Conference, Friday, September 18 at 10:15 am ET
A live audio webcast of each presentation will be available by visiting the "Investors" section of the Arcus website at www.arcusbio.com. A replay of each webcast will be available for at least two weeks following the live event.

On August 27, 2020 Treadwell Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for highly aggressive cancers, reported the initiation of three expansion cohorts in its ongoing Phase 1 study evaluating CFI-402257, a selective and highly potent oral inhibitor of tyrosine threonine kinase (TTK) (Press release, Treadwell Therapeutics, AUG 27, 2020, View Source [SID1234564114]). The expansion cohorts include ER+/HER2 breast cancer patients in combination with fulvestrant post CDK4/6 inhibitor failure, triple negative breast cancer patients and an additional cohort in solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"CFI-402257 is a potentially best-in-class, highly selective and potent inhibitor of TTK, a critical component of the cancer cell’s maintenance of genomic integrity and survival, which may be a key vulnerability of tumors that are resistant to CDK4/6 inhibitors," said Dr. Mark Bray, Treadwell Chief Scientific Officer and Co-Founder. "We are very encouraged by the compelling early signs of clinical activity of CFI-402257 as a monotherapy in the dose escalation portion of our Phase 1 study, and we look forward to continuing to evaluate the potential of our TTK inhibitor in combination therapy through our expansion cohorts."

"Patients with ER+/Her2- breast cancer face a high unmet medical need, as a majority of these patients become resistant to CDK4/6 inhibitors. We are very pleased by the initial indications of clinical activity in this patient segment and are excited to advance to the next phase of the study to evaluate the potential of CFI-402257 as a treatment for these patients," said Philippe Bedard, M.D., Princess Margaret Cancer Centre, primary investigator of the study.

The open-label Phase 1 trial of CFI-402257 is designed to assess the safety, tolerability, pharmacokinetics, and clinical benefit of treatment with CFI-402257. The study consists of two parts, the dose escalation portion, now completed, in which escalating doses were administered orally in patients with advanced cancer that was refractory to current treatment or for which no curative therapy exists. The dose expansion portion of the multi-center trial will enroll up to 52 patients across sites in Canada in three parallel arms: patients with ER+/HER2-negative breast cancer who have failed CDK4/6 inhibitors in combination with an approved endocrine treatment (fulvestrant); patients with triple negative breast cancer (TNBC); and patients with advanced solid tumors. Dr. Philippe Bedard of the Princess Margaret Cancer Centre is the primary investigator, and Dr. John Hilton (Ottawa Hospital Cancer Center) and Dr. Daniel Renouf (British Columbia Cancer Agency) are co-investigators of the study.

CFI-402257 is a potentially best-in-class inhibitor of TTK protein kinase. TTK is a dual-specificity serine-threonine kinase that is critical for the spindle assembly checkpoint (SAC), chromosome alignment and error correction. Inhibition of TTK kinase activity causes cells to prematurely exit mitosis with unattached chromosomes, resulting in severe chromosome missegregation, aneuploidy and eventually cell death. TTK is overexpressed in several tumors, and higher levels correlate with worse prognosis, and may contribute to the survival and proliferation of aneuploid cells. During initial preclinical screening studies, CFI-402257 demonstrated a desirable combination of potent inhibition of cancer cell growth and high oral bioavailability with robust suppression of tumour growth achieved upon at tolerated doses in in vivo studies.

On August 27, 2020 Median Technologies (Paris:ALMDT), The Imaging Phenomics Company, reported the publication date for its half year results 2020 (Press release, MEDIAN Technologies, AUG 27, 2020, View Source [SID1234564113]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Publication

Date

2020 half year results

October 14, 2020*

On August 27, 2020 CURE Media Group, the industry-leading multimedia platform devoted to cancer updates and research that reaches more than 1 million patients, reported the three finalists for the 2020 Extraordinary Healer Award for Oncology Nursing and the winner of the 2020 The Finest Hour award (Press release, CURE Media Group, AUG 27, 2020, View Source [SID1234564112]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This year’s celebration, which will be held in a virtual format, recognizes exceptional nurses for their efforts in the oncology community. The Finest Hour, an award to honor the selfless achievements of an extraordinary nurse working to provide care during the COVID-19 pandemic, also will be presented.

This year’s finalists for the Extraordinary Healer award are:

Vicki Dodson, B.S.N., RN, OCN, has 36 years of nursing experience. She works as an oncology nurse navigator at Providence Sacred Heart Medical Center in Spokane, Washington. Dodson takes time to listen to patients expressing their fears and frustrations and helps them figure out the confusing health care system, educating them on the treatments and therapies they will be receiving. She recently volunteered to run a cancer support group that had lost its facilitator, in addition to the many other organizations she supports. Dodson credits her career in nursing to her love of people and the ever-everchanging research and treatment.
Maria Rodriguez, B.S.N., RN, is a nurse navigator at the cancer center at Temple University Hospital in Philadelphia, Pennsylvania. Rodriguez looks beyond patients’ diagnoses and tries to soothe the spirit in addition to treating the illness. She is bilingual and became a dual-role medical interpreter for Spanish-speaking patients. Rodriguez made the cancer center’s holiday food drive more inclusive for Hispanic families and spearheaded the center’s Feliz Navidad celebration. Her inspiration for becoming a nurse was her grandmother, who always told her that she had healing hands and to share them with others who were suffering because of an illness.
Christie Santure, B.S.N., RN, OCN, is an infusion nurse at UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania. Santure launched a Caring for the Caregiver program at UPMC, a support group for those who are caring for someone undergoing cancer treatment. She offers sessions twice a month at Hillman Cancer Center and is working with leadership to start the program at other UPMC locations. Santure started as a candy-striper and has been a nurse for 40 years. She aspires to walk in the shoes of the nurses before her who inspired her journey.
The winner of the Finest Hour award is Elizabeth Farrat, B.S.N., RN, CCRN-K. Farrat works as a perioperative nurse liaison in the operating room at Memorial Sloan Kettering (MSK) Cancer Center in New York City. Prior to her current role, Farrat worked in the intensive care unit (ICU) at MSK for 10 years, where she helped design and facilitate the ICU orientation trajectory, ICU preceptor expectations and workflow. In addition, she helped create an ICU Teaching the Teacher Continuing Education Program for ICU preceptors. Farrat also was a palliative care unit champion and is an end-of-life nursing education consortium critical care trainer. During the COVID-19 surge in New York, Farrat was redeployed to the ICU to care for patients who were critically ill with the virus. She helped implement the real-time, critical-care training of step-down registered nurses so that they were able to provide ICU care.

"Each of these nurses has demonstrated incredible compassion, expertise and helpfulness in caring for their patients," said Mike Hennessy Jr., president, and CEO of MJH Life Sciences, parent company of CURE Media Group. "They have gone above and beyond their call of duty during this difficult time, and we look forward to shining a light on them for their tremendous efforts."

The 2020 Extraordinary Healer Award for Oncology Nursing virtual celebration will take place Thursday, Sept. 17.

For more information on the winners and to register to attend, click here.

This event is supported by Bristol Myers Squibb and Janssen.